TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Clinical trials for TRIPLE-NEGATIVE BREAST CANCER (TNBC) explained in plain language.
Never miss a new study
Get alerted when new TRIPLE-NEGATIVE BREAST CANCER (TNBC) trials appear
Sign up with your email to follow new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can your own immune cells fight advanced cancer?
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 08, 2026 00:03 UTC
-
Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
Disease control Not yet recruitingThis early-phase trial is testing a personalized cancer vaccine called BreakVax, designed from each patient's own tumor, in combination with immunotherapy and chemotherapy for advanced triple-negative breast cancer. The goal is to see if this multi-pronged approach can safely boo…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: BreakBio Corp • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a drug combo outsmart a tough breast cancer subtype?
Disease control Not yet recruitingThis phase III trial is testing whether adding everolimus to trastuzumab rezetecan helps people with a specific subtype of triple-negative breast cancer (called luminal androgen receptor) live longer without their disease progressing. The study enrolls adults with advanced or met…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new drug combo outsmart triple-negative breast cancer?
Disease control Not yet recruitingThis phase 2 trial is investigating whether adding an experimental drug called retlirafusp alfa to standard chemotherapy or to another drug called fuzuloparib can improve outcomes for people with triple-negative breast cancer (TNBC). The study includes two groups: one with early-…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a biomarker spare breast cancer patients from harsh chemo?
Disease control Not yet recruitingThis trial explores whether people with early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes (TILs) can safely skip a class of chemotherapy drugs called anthracyclines, which are effective but can harm the heart. Participants receive 12 week…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a targeted drug plus immunotherapy outsmart tough breast cancer?
Disease control Not yet recruitingThis phase III trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy (PD-1 antibody), works better than standard chemotherapy plus immunotherapy for people with advanced triple-negative breast cancer that has a specific protein (PD-L1). The study inc…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a modified protein help immunotherapy fight a tough breast cancer?
Disease control Not yet recruitingThis study investigates whether adding isunakinra, a modified protein that blocks inflammation, can make triple-negative breast cancer more sensitive to standard immunotherapy and chemotherapy. The trial enrolls adults with newly diagnosed, locally advanced triple-negative breast…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Triple-Drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a combination of three drugs—tislelizumab, bevacizumab, and capecitabine—in people with advanced solid tumors. The trial focuses on two challenging groups: those whose cancers have stopped responding to immunotherapy and those with tumors that have spread to the …
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called CT-202 in people with advanced triple-negative breast cancer, colorectal cancer, or bladder cancer that has come back or spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells that have a pro…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: drug combo trial launches
Disease control Not yet recruitingThis phase 3 trial is testing a drug called trastuzumab rezetecan, alone or combined with bevacizumab, in 140 women with advanced triple-negative breast cancer that has a specific immune-suppressed pattern. The goal is to see if the combination can delay cancer growth better than…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill takes on tough breast cancer in first human trial
Disease control Not yet recruitingThis early-phase trial tests an oral drug called Zn-Telomir in 76 adults with advanced or metastatic triple-negative breast cancer that has worsened after prior treatments. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. It is…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Telomir Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Hard-to-Treat breast cancer: experimental combo enters phase 2
Disease control Not yet recruitingThis study tests a new drug, QLC5513, alone or with another drug (QL1706) in 60 women with advanced triple-negative breast cancer that has worsened after at least one prior treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Participants wi…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for tough breast cancer: targeted pill after chemo shows promise in large trial
Disease control Not yet recruitingThis study tests whether taking the oral drug everolimus after standard chemotherapy can help prevent breast cancer from coming back in people with a specific subtype of triple-negative breast cancer called LAR. The trial will enroll 904 women who have had surgery for early-stage…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New cocktail of drugs aims to wipe out aggressive breast cancer before surgery
Disease control Not yet recruitingThis early study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (olaparib), and chemotherapy (paclitaxel) given before surgery to 20 women with early, high-risk triple negative breast cancer that has a specific DNA repair defect …
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: NA • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental Triple-Drug cocktail targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThis early-phase study will test a combination of three drugs—camrelizumab (an immunotherapy), pirfenidone (an anti-fibrotic drug), and standard chemotherapy—in 12 women with advanced triple-negative breast cancer that has already been treated with immunotherapy. The goal is to s…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1, PHASE2 • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jun 26, 2026 14:30 UTC
-
New drug cocktail aims to shrink Hard-to-Treat breast tumors
Disease control Not yet recruitingThis Phase 2 trial is testing a combination of two drugs—Sacituzumab tirumotecan and Tagitanlimab—in people with a specific type of advanced breast cancer called PD-L1-positive triple negative breast cancer. The study will enroll 47 participants whose cancer has already been trea…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:58 UTC
-
New radioactive antibody could light up Hard-to-Treat cancers
Diagnosis Not yet recruitingThis early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Phase: PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
New blood test aims to predict which cancer patients will benefit from immunotherapy
Diagnosis Not yet recruitingThis study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Sponsor: OncoHost Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
Blood test may reveal if breast cancer treatment is working
Knowledge-focused Not yet recruitingThis study looks at whether tracking tumor DNA in the blood (ctDNA) can help doctors see how well breast cancer treatment is working before surgery. It will include 186 people with stage II-III HER2-positive or triple-negative breast cancer. Researchers will take blood samples at…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Sponsor: Federico II University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study to reveal hidden toll of breast cancer drugs on fertility
Knowledge-focused Not yet recruitingThis study will follow 75 women aged 18-42 with early-stage triple-negative breast cancer who are receiving chemotherapy plus immunotherapy before surgery. Researchers will measure hormone levels, track menstrual patterns, and use questionnaires to see how treatment affects ovari…
Matched conditions: TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC